AstraZeneca, China and FibroGen

AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal
AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia drug in the country, further boosting its presence in the world's second-biggest economy.
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million
Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent.
AstraZeneca pays $160M for FibroGen's China unit, regional rights to roxadustat
AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat.
FibroGen China sale ‘shrewd strategic transaction,’ says H.C. Wainwright
H.C. Wainwright analyst Matthew Keller keeps a Buy rating on FibroGen (FGEN) with a $10 price target after the company announced the sale of
AstraZeneca deepens China presence with FibroGen deal
The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there.
US' FibroGen to Sell China Unit to AstraZeneca for USD160 Million
AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other unlicensed market rights and continue to evaluate a development plan for the drug in anemia associated with lower-risk myelodysplastic syndrome.
AstraZeneca to buy FibroGen's China unit for $160 million
AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence in the country despite growing US-China trade tensions. Fibrogen said the deal will give AstraZeneca full rights to its anemia drug roxadustat in China.
M&A News: AstraZeneca Expands China Footprint With FibroGen Deal
AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal
By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially resuming development of roxadustat in another indication.
FibroGen to sell China business, extend cash runway to focus on cancer drugs
The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...
FibroGen (NASDAQ:FGEN) vs. Roche (OTCMKTS:RHHBY) Head to Head Survey
FibroGen (NASDAQ:FGEN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the ...
pharmaphorum23h
AstraZeneca builds in China as Cosette buys Mayne
The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...
FiercePharma22h
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
Yahoo Finance3d
FibroGen, Inc. (FGEN)
Fibrogen said the deal will give AstraZeneca full rights to its anemia drug roxadustat in China. In December, AstraZeneca, which got about 12% of its 2024 sales from China, said it would buy ...